CJC-1295 5mg

Research applications

• GHRH receptor binding and activation studies
• Growth hormone secretion research in animal models
• Albumin-binding pharmacokinetic research (DAC technology)
• Comparative research against unmodified GHRH(1-29) analogues

What the literature reports on CJC-1295

CJC-1295 is derived from the first 29 amino acids of native human GHRH, with substitutions at several positions designed to resist degradation by DPP-4 and other peptidases. The DAC-conjugated variant covered here adds a maleimidopropionyl group at the C-terminal lysine, a modification documented in the original medicinal chemistry literature as promoting selective, irreversible binding to a free cysteine residue on serum albumin.

Pharmacokinetic research

The albumin-binding DAC technology used in CJC-1295 has been studied specifically for its effect on circulating half-life, with pharmacokinetic research reporting substantially extended plasma retention compared with unmodified GHRH or the no-DAC variant of CJC-1295. This research has positioned DAC conjugation as a case study in half-life extension strategies for short regulatory peptides.

Growth hormone axis research

Animal studies using CJC-1295 have reported sustained elevation of growth hormone and downstream insulin-like growth factor 1 (IGF-1) levels over extended observation windows, consistent with its prolonged receptor engagement. This research is often discussed alongside studies of pulsatile versus sustained GHRH receptor activation and its differential effects on pituitary somatotroph signalling.

Comparative GHRH-analogue research

Because CJC-1295 without DAC (also studied under the name Modified GRF 1-29) shares the same core 29-residue sequence but lacks the albumin-binding moiety, researchers frequently compare the two variants to isolate pharmacokinetic effects from receptor pharmacology. This comparative approach also extends to combination research with ghrelin-receptor agonists such as Ipamorelin, examined in the CJC-1295 + Ipamorelin blend listing.

Nomenclature research note

Researchers should note that the commercial peptide market has been documented to inconsistently apply the CAS numbers for the DAC and no-DAC variants of CJC-1295, with some vendor listings pairing the no-DAC CAS number with a "with DAC" product description. Cross-referencing the batch certificate of analysis for both molecular weight and sequence is recommended practice when identity confirmation matters to the research protocol.

Laboratory handling

CJC-1295 should be stored as lyophilised powder at -20°C, protected from light and moisture, until reconstitution. Reconstitution follows standard peptide practice, introducing diluent slowly along the vial wall and mixing gently rather than shaking, to preserve the integrity of the DAC-conjugation site.

• Lyophilised powder: store at -20°C, protected from light, until reconstitution.
• Reconstitution: introduce diluent slowly along the vial wall; mix gently, do not shake.
• Post-reconstitution: 2-8°C for short-term laboratory use; avoid repeated freeze-thaw cycles.
• Each batch ships with a certificate of analysis confirming ≥99% purity by HPLC and identity by mass spectrometry.

See the peptide reconstitution and storage guide for a full protocol reference. This product is intended for laboratory research use only.